Invest-in-America
6日前
HOTH: Not yet, Homeboy. (I simply spotted THIS one in the Pre-Market today, when it suddenly popped-up at the BOTTOM of Benzinga's nice, short, Pre-Market-Runners, LIST --- an item which then soared near the TOP thereof rapidly.)
https://i.giphy.com/media/v1.Y2lkPTc5MGI3NjExa2RjN3k2cTdwbThoNzFqaHVwdGk3ZWpzYjVqcWh3czE0MHZpOG44biZlcD12MV9pbnRlcm5hbF9naWZfYnlfaWQmY3Q9Zw/R51a8oAH7KwbS/giphy.gif
///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////
Invest-in-America
6日前
HOTH: A classic NO-Brainer, Bro!! (And I myself DO qualify in THAT regard --- truth-be-told; heck, see film-clip of ME & my Girl Friend, just yesterday, on the way to school way over here in San Diego,CA!!)
"Stupid is, as stupid DOES, Sweetheart!"
///////////////////////////////////////////////////////////////////////////////////////////////////////
subslover
3週前
Yeah, the News is interesting😆 = Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment
Hoth Therapeutics Enters Exclusive Patent License Agreement with VA and Emory University
Hoth Also Expands Its' Intellectual Property to Further Its' Market Opportunity for HT-001
NEW YORK, Dec. 26, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing innovative therapies, today announced that it has entered into an exclusive patent license agreement with the U.S. Department of Veterans Affairs (VA). This agreement provides Hoth with exclusive rights to a jointly owned patent portfolio co-developed by the VA and Emory University.
The licensed technology centers on "Glial Cell Line-Derived Neurotrophic Factor, Obesity, and Obesity-Related Diseases and Conditions," a groundbreaking innovation aimed at addressing critical challenges in treating obesity and associated health conditions. This agreement underscores Hoth Therapeutics' commitment to advancing transformative healthcare solutions.
Under the terms of the agreement, Hoth Therapeutics will have exclusive rights to develop, market, and commercialize products and processes derived from the licensed patents. The VA and Emory University have granted Hoth this license to further develop the technology with the goal of ensuring the benefits of this innovation are accessible to the widest audience possible.
"We are honored to collaborate with the VA and Emory University to bring this cutting-edge technology to market," said Robb Knie, Chief Executive Officer of Hoth Therapeutics. "This partnership represents a significant milestone in our efforts to address obesity and related health conditions with innovative, science-driven solutions. We look forward to advancing this critical work to improve the lives of patients worldwide."
The agreement includes a comprehensive development plan, ensuring the continued progress of this technology from the research phase through commercialization. Hoth Therapeutics plans to leverage its expertise and resources to bring the licensed products to the point of practical application while adhering to rigorous development benchmarks.
This collaboration exemplifies Hoth's dedication to fostering partnerships that advance scientific discoveries into therapeutic solutions. The company remains steadfast in its mission to improve patient outcomes and address unmet medical needs.
Hoth has also entered into an agreement to further protect its intellectual property by signing an LOI to acquire additional provisional patent protection for its lead therapeutic HT-001. The additional intellectual property expands HT-001's reach to other cancer therapeutics.
About Hoth Therapeutics, Inc.
subslover
3月前
Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study
NEW YORK, Oct. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing new generation therapies for unmet medical needs, is excited to announce highly promising early data from a preclinical study of its latest cancer treatment. The preliminary results demonstrate that the treatment successfully stabilizes tumor growth with remarkable consistency across subjects, showing potential as an effective therapeutic option in oncology. This study was performed and took place under a sponsored scientific research agreement with NC State University.
The study measured tumor volumes in treated and untreated subjects over the course of the experiment. Tumor volume measurements in the treated group exhibited minimal changes, suggesting that the treatment effectively inhibited tumor growth. Additionally, all tumors in the treated animals displayed remarkable consistency in volume, with standard deviation error bars barely visible—a strong indication of the treatment's uniformity and reproducibility in suppressing tumor growth.
"These early findings are incredibly encouraging and demonstrate that our treatment has the potential to halt tumor progression consistently across subjects," said Robb Knie, CEO of Hoth Therapeutics. "The stability and low variability observed in tumor volumes among treated animals are indicative of a promising therapeutic effect, and we're excited to move forward with further testing as we process additional tissue data."
Key observations from the initial data include:
Stabilized Tumor Growth: Tumor volumes in treated subjects remained remarkably stable over the course of the study, suggesting that the treatment may significantly inhibit tumor growth.
Consistency Across Subjects: Tumor sizes were highly consistent across all treated animals, as demonstrated by the minimal error bars on the graph. This uniform response highlights the treatment's potential reproducibility and reliability.
Comparison with Untreated Controls: In contrast, untreated subjects showed greater variability and an increase in tumor volume, underscoring the potential efficacy of the treatment in slowing or halting tumor growth.
As Hoth Therapeutics advances this research, the company will continue analyzing additional tissue data to further validate these results. The company is committed to moving forward with the development of this promising treatment and exploring its full potential for patients in need of effective cancer therapies.
For more information on Hoth Therapeutics' development programs, please visit www.hoththerapeutics.com.
subslover
3月前
Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway
NEW YORK, Oct. 15, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative treatments, is proud to announce the granting of a U.S. patent for its pioneering Alzheimer's treatment, HT-ALZ. This milestone patent secures the company's intellectual property rights to its novel therapeutic approach, as Hoth accelerates preparations for clinical trials.
HT-ALZ represents a breakthrough in Alzheimer's treatment, specifically targeting the Substance P/Neurokinin-1 Receptor pathway. This pathway is known to play a critical role in neuroinflammation, which is increasingly recognized as a driving factor in the progression of Alzheimer's disease. Preclinical studies have shown promising results, including reduced neuroinflammation and significant improvements in cognitive functions such as memory and learning.
The patent solidifies Hoth's leadership in the development of Alzheimer's therapies and paves the way for the next phase of human clinical trials. Formulation of HT-ALZ for these trials is currently underway, with the goal of advancing this promising treatment to patients as swiftly as possible.
Next Steps
As Hoth Therapeutics completes the formulation phase, the company will look to prepare clinical trials to further validate HT-ALZ's efficacy in humans. The upcoming trials will focus on demonstrating the drug's safety, tolerability, and effectiveness in slowing or reversing the cognitive decline associated with Alzheimer's disease.
Robb Knie, CEO of Hoth Therapeutics, commented, "This patent marks a significant achievement for Hoth as we progress HT-ALZ from the lab to clinical development. The preclinical data on neuroinflammation reduction and cognitive improvement offer great hope, and we are excited to take the next critical steps toward delivering a potentially life-changing therapy to Alzheimer's patients."
About HT-ALZ
HT-ALZ represents a novel approach in Alzheimer's research, focusing on the modulation of neuroinflammation, unlike many treatments that focus solely on amyloid plaques. Preclinical data has shown that HT-ALZ effectively reduces reactive astrocytes in the brain, cells that contribute to the inflammatory processes seen in Alzheimer's, leading to improved cognitive outcomes in experimental models.
For more information about Hoth Therapeutics and HT-ALZ, please visit www.hoththerapeutics.com.
TIMGZ
4月前
Hoth Therapeutics Received Institutional Review Board Approval From The Montefiore Medical Center And The Dana-Farber Cancer Institute To Proceed With Its First-In-Human Phase 2a Clinical Trial Of HT-001 For The Treatment Of Skin Toxicities Associated With Epidermal Growth Factor Receptor Inhibitors
BENZINGA 10:37 AM ET 9/5/2024
Symbol Last Price Change
HOTH 1.24down +0.5301 (+74.6725%)
QUOTES AS OF 11:30:15 AM ET 09/05/2024
Dana-Farber Cancer Institute in Boston, MA and Montefiore Medical Center in New York, NY Join Clinical Trial
NEW YORK, Sept. 5, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc.(HOTH) , a patient-focused biopharmaceutical company, today announced today that it has received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).
Hot Features
プレミアム
登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。
maximus_art
5日前
TheFinalCD
5日前
Zardiw
5日前
Monksdream
6日前
INV4
6日前
glenn1919
3週前
georgie18
4月前
Surfacetite
4月前
motleytool
4月前
PonkenPlonken
4月前
